L3VLUP
ProSign in

COO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

COOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • COO
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCOOVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 2022none listed holders, n.a.22 holders, $18.4bn
Q4 2022none listed holders, n.a.28 holders, $18.4bn
Q1 2023none listed holders, n.a.26 holders, $21.4bn
Q2 2023none listed holders, n.a.27 holders, $24.7bn
Q3 2023none listed holders, n.a.33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 202421 holders, $3.0bn31 holders, $29.8bn
Q2 202419 holders, $2.5bn29 holders, $33.4bn
Q3 202419 holders, $3.3bn27 holders, $33.5bn
Q4 202416 holders, $2.9bn26 holders, $28.5bn
Q1 202519 holders, $3.2bn21 holders, $35.4bn
Q2 202521 holders, $3.0bn21 holders, $32.3bn
Q3 202516 holders, $3.2bn22 holders, $25.9bn
Q4 202517 holders, $3.4bn26 holders, $31.8bn
Q1 202613 holders, $2.6bn25 holders, $31.8bn
Q2 202619 holders, $2.6bn26 holders, $34.6bn
COO

Cooper Cos Inc

Holders
17
Reported value
$3.4bn
Buyers
13
Sellers
20

Breadth -7 among 92 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only COO (6)

AQR Capital Management LLC, ExodusPoint Capital Management LP, GAMCO Investors Inc, Jana Partners, Schonfeld Strategic Advisors LLC, Tudor Investment Corp

Only VRTX (15)

Acadian Asset Management LLC, ARK Investment Management LLC, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Two Sigma Advisers LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →